Lighthouse Biotech
LIGHTHOUSE BIOTECH SRL: FROM A SIMPLE BLOOD SAMPLE WE IDENTIFY AND EXTRAC CANCER CELLS
Lighthouse Biotech is a project aimed at extracting circulating tumor cells from a simple blood draw, keeping them intact to avoid alteration of their metabolism, making them traceable even in very early stages of the disease.
The separation process developed enables storing these cells in biobanks, using them in cell cultures to create artificial disease models for drug testing, or analyzing the cells to clarify disease mechanisms, understand the patient’s condition, and, most importantly, recommend personalized therapies.
The research project was developed by the founding members of Lighthouse Biotech:
Fabio Del Ben, a medical doctor in clinical pathology and clinical biochemistry at the University of Udine with a Ph.D. in Nanotechnology from the Graduate School of Nanotechnology in Trieste, a Master’s in Complex Actions from SISSA, and software programming training from National Instruments in Milan; and Matteo Turetta, a medical director in clinical pathology and microbiology at the Oncological Center of Aviano, with a Master’s in Complex Actions from SISSA.
The patent was developed within the CRO of Aviano, University of Udine, and Radboud University Nijmegen (Netherlands).
Utopia invested in 2021.
